Obiettivo
Age-related macular degeneration (AMD) is the world’s most important age-related blinding disorder. The current proposal utilises epidemiological data describing clinical phenotype, molecular genetics, lifestyle, nutrition, and in-depth retinal imaging derived from existing longitudinal European epidemiological cohorts and biobanks to provide three major insights needed for long-lasting prevention and therapy for AMD: (a) the development of robust algorithms utilising genetic and non-genetic risk factors to identify personalised risks of developing advanced wet and dry AMD; (b) the identification of novel biomarkers for further stratification of disease risks.
New insights from (a)+(b) will be used to elaborate preventive medical recommendations for highrisk subgroups of AMD patients; and (c) the identification of molecular drivers/biological pathways relevant for onset and progression of advanced AMD that will be used to identify and validate new therapeutic targets.
Key deliverables are:
1. Determination of AMD frequency in Europe, and assessment of AMD risk for phenotypical, genetic, environmental, and biochemical risk factors and their interaction. (WP1-3)
2. Development of a web-based prediction model for personalised risk assessment of AMD based on integration of risk profiles derived from retinal imaging, molecular genetics, assessment of lifestyle, and biochemical testing. (WP4)
3. Modelling and functional characterisation of pathophysiological pathways identified from integrated analysis of current knowledge and the above risk profiles. (WP5)
4. Experimental testing and interpretation of pathophysiological consequences of risks at the molecular level. (WP6)
5. An extension and refinement of the prediction model (WP4) based on work in WP5 and WP6 to generate clinical guidelines for the medical management of high-risk subgroups of patients with AMD. (WP7)
6. Promotion and dissemination of newly gained knowledge towards AMD prevention and therapy development
Campo scientifico
- medical and health scienceshealth sciencespublic healthepidemiology
- natural sciencesbiological sciencesbiochemistrybiomoleculesproteins
- medical and health sciencesclinical medicineophthalmology
- medical and health sciencesmedical biotechnologycells technologiesstem cells
- medical and health scienceshealth sciencesnutrition
Programma(i)
Argomento(i)
Invito a presentare proposte
Vedi altri progetti per questo bandoBando secondario
H2020-PHC-2014-two-stage
Meccanismo di finanziamento
RIA - Research and Innovation actionCoordinatore
72074 Tuebingen
Germania
Mostra sulla mappa
Partecipanti (14)
3015 GD Rotterdam
Mostra sulla mappa
08003 Barcelona
Mostra sulla mappa
6525 XZ Nijmegen
Mostra sulla mappa
33000 Bordeaux
Mostra sulla mappa
Soggetto giuridico diverso da un subappaltatore che è affiliato o legalmente collegato a un partecipante. Il soggetto svolge le attività secondo le condizioni stabilite nell’accordo di sovvenzione, fornisce beni o servizi per l’azione, ma non ha sottoscritto l’accordo di sovvenzione. Una terza parte rispetta le regole applicabili al suo partecipante correlato ai sensi dell’accordo di sovvenzione per quanto riguarda l’ammissibilità dei costi e il controllo delle spese.
75654 Paris
Mostra sulla mappa
WC1E 6BT London
Mostra sulla mappa
08022 BARCELONA
Mostra sulla mappa
52074 Aachen
Mostra sulla mappa
50829 Cologne
Mostra sulla mappa
L’organizzazione si è definita una PMI (piccola e media impresa) al momento della firma dell’accordo di sovvenzione.
4070 Basel
Mostra sulla mappa
Partecipazione conclusa
EC1V 2PD London
Mostra sulla mappa
41092 Sevilla
Mostra sulla mappa
BT7 1NN Belfast
Mostra sulla mappa
4 Dublin
Mostra sulla mappa